Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit

BACKGROUND: The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14α-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chen, Chiung-Kuang, Doyle, Patricia S., Yermalitskaya, Liudmila V., Mackey, Zachary B., Ang, Kenny K. H., McKerrow, James H., Podust, Larissa M.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2629123/
https://ncbi.nlm.nih.gov/pubmed/19190730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0000372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados